StonvexLoading…
StonvexStonvexStonvexReal-time TradingView chart with full indicator set.
Last 7 days, powered by Finnhub. Tap Analyze to classify direction.
Loading latest news…
Pick the depth your tier unlocks. Logged-in Pro/Premium users automatically get the deeper report.
Free preview · 3 reports / hour · No sign-up required
Factor grades, AI Copilot, personalized ranking, and deeper event analysis.
Upgrade to Pro →6-factor scoring with sector-relative rank. Updated daily.
Each row shows where RCKT sits in our scored universe today on a single observational measurement. P85 means RCKT ranks above 85% of peers on that factor right now. Percentile rankings are descriptive — they are not buy/sell signals or quality judgments. Universe refreshed every 60 seconds.
Today's volume vs prior session average.
Absolute daily price move vs peers.
24h article count relative to the universe.
AI-classified polarity of recent news.
Today's dollar turnover (volume × VWAP).
Signed daily return vs the rest of the universe.
Stonvex publishes percentile measurements as observational data only. Nothing here constitutes a recommendation, prediction, or advice about whether to buy, sell, or hold any security. Stonvex is not a registered investment advisor.
Share this analysis with other traders
Disclaimer: The content on this page is for informational and educational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any security. Past performance does not guarantee future results. Consult a licensed financial advisor before making any investment decisions.
No sell-side coverage available for RCKT yet.
Common for small-cap names, ETFs, recent IPOs, and ADRs without US-listed sell-side coverage. When analysts publish, ratings appear here within one business day.
| Date | Open | Close | Δ | Vol |
|---|---|---|---|---|
| 05-15 | $3.37 | $3.25 | -3.56% | 1.9M |
| 05-18 | $3.26 | $3.07 | -5.83% | 3.1M |
| 05-19 | $3.07 | $2.92 | -4.89% | 2.9M |
| 05-20 | $2.94 | $2.97 | +1.02% | 2.6M |
| 05-21 | $2.95 | $3.11 | +5.42% | 2.8M |
Indicator values from Polygon. Educational only — single- indicator triggers in isolation are not a complete trading signal.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. It has one reportable segment related to R&D and commercial readiness of its gene therapies.
Documents are served directly from sec.gov / the issuer's website — Stonvex does not proxy or store filings.
Quarterly filings sourced directly from SEC EDGAR. Real-time earnings actuals are in the Earnings panel above.
| Metric | Q1 2026 2026-03-31 | Annual 2025 2025-12-31 | Q3 2025 2025-09-30 | Q2 2025 2025-06-30 |
|---|---|---|---|---|
Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
Operating Income | $-48.51M | $-231.75M | $-187.78M | $-135.54M |
Net Income | $-47.59M | $-223.12M | $-180.59M | $-68.92M |
EPS (Diluted) | $-0.42 | $-2.01 | $-1.63 | $-1.18 |
Total Assets | $285.41M | $330.45M | $368.03M | $420.98M |
Total Liabilities | $47.37M | $53.23M | $54.36M | $66.77M |
Cash & Equivalents | $49.61M | $77.56M | $75.95M | $32.82M |
Free Cash Flow OCF − CapEx | $-45.49M | $-190.45M | $-155.53M | $-105.17M |
Shares Outstanding | 109.12M | 108.32M | 108.21M | 107.88M |
Latest Form 13F-HR disclosures from the curated Super Investors list. Click through to see each manager's full long book.